

# Engineering Nanobodies for Biotechnological Applications

**G. Ortega**<sup>1,2,\*</sup>

<sup>1</sup>Precision Medicine and Metabolism Lab, CIC bioGUNE, 48160 Bilbao, Spain

<sup>2</sup>Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain

e-mail: gortega@gmail.com

Tailoring proteins to suit specific applications will improve their use in biosensors, as well as in many other biotechnological applications. This is, however, an important challenge in biomolecular engineering. In response, research in my group focuses on developing rational engineering strategies to improve the properties of proteins. To do that, we are combining new computational and artificial intelligence tools with molecular biophysics. [1]

Among the large set of proteins of biotechnological relevance, nanobodies stand out due to their versatility and simplicity. Derived from camelid single-domain antibodies, these minimalistic antibodies offer antigen-binding capabilities very similar to canonical antibodies, but at a fraction of their size. Nanobodies have thus found widespread application in biosensors, but also in immunotherapy, imaging and drug delivery.

Aiming to expand the implementation of nanobodies in biosensors and other biotechnologies, we have focused on engineering the conserved scaffold region of nanobodies to improve their stability, solubility, and production, as well as to introduce new functionalities. More specifically, we have developed new nanobody variants capable of undergoing conformational changes upon binding of their antigen. These receptors thus support conformational signaling, enabling more direct signal transduction and facilitating the development of reagent-less biosensors [2]. Leveraging this, we have developed a biosensor for the hormone chorionic gonadotropin, a biomarker used to monitor the development of pregnancy.

This work showcases our ability to engineer the properties and functional versatility of nanobodies, and potentially other proteins. Optimizing nanobodies rationally will facilitate the development of new biosensors supporting continuous measurements [3], but also their implementation in other biotechnologies. For example, improving nanobody stability will facilitate their use as therapeutic agents; and increasing their production yield in recombinant protein expression systems will facilitate their industrial production. In addition, the high similarity between nanobodies for different antigens will facilitate the expansion of our approach to other nanobodies against drugs, hormones and biomarkers.

## References

- [1] R. Núñez-Franco, A. Torres-Mozas, C.D. Navo, A. Schedlbauer, M. Azkagorta, I. Illoro, F. Elortza, G. Ortega, O. Millet, F. Peccati, G. Jiménez-Osés, *bioRxiv* doi:10.1101/2023.09.08.556816 (2023).
- [2] A. Chamorro-García, G. Ortega-Quintanilla, A. Idili, C. Parolo, *International Encyclopedia of Public Health 3rd Edition* doi: 10.1016/B978-0-323-99967-0.00266-0 (2024).
- [3] N. Arroyo-Currás, G. Ortega, D.A. Copp, K.L. Ploense, Z.A. Plaxco, T.E. Kippin, J.P. Hespanha, K.W. Plaxco, *ACS Pharmacol Transl Sci* **1**(2):110-118 (2018).